Are higher circulating lipoprotein (a) levels associated with increased all-cause and cardiovascular mortality in the general population and patients with CVD?
Higher Lp(a) levels are associated with increased all-cause and cardiovascular mortality, supporting ESC/EAS guidelines to measure Lp(a) at least once in adults.
This study provides further evidence that higher Lp(a) levels are associated with higher risk of all-cause mortality and CVD-death in the general population and in patients with CVD. These findings support the ESC/EAS Guidelines that recommend Lp(a) should be measured at least once in each adult person's lifetime, since our study suggests those with higher Lp(a) might also have higher risk of mortality.
Amiri et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: